A citation-based method for searching scientific literature

L Paz-Ares, E-H Tan, K O'Byrne, L Zhang, V Hirsh, M Boyer, J C-H Yang, T Mok, K H Lee, S Lu, Y Shi, D H Lee, J Laskin, D-W Kim, S A Laurie, K Kölbeck, J Fan, N Dodd, A Märten, K Park. Ann Oncol 2017
Times Cited: 312



Kazuhiko Nakagawa, Edward B Garon, Takashi Seto, Makoto Nishio, Santiago Ponce Aix, Luis Paz-Ares, Chao-Hua Chiu, Keunchil Park, Silvia Novello, Ernest Nadal, Fumio Imamura, Kiyotaka Yoh, Jin-Yuan Shih, Kwok Hung Au, Denis Moro-Sibilot, Sotaro Enatsu, Annamaria Zimmermann, Bente Frimodt-Moller, Carla Visseren-Grul, Martin Reck. Lancet Oncol 2019
Times Cited: 263




List of shared articles



Times cited

Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
Hidetoshi Hayashi, Ernest Nadal, Jhanelle E Gray, Andrea Ardizzoni, Nicola Caria, Tarun Puri, Christian Grohe. Clin Lung Cancer 2022
12


Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells.
Yuki Katayama, Tadaaki Yamada, Shinsaku Tokuda, Naoko Okura, Naoya Nishioka, Kenji Morimoto, Keiko Tanimura, Yoshie Morimoto, Masahiro Iwasaku, Mano Horinaka,[...]. Cancer Med 2022
1

Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation.
Chih-Hsi Scott Kuo, Tzu-Hsuan Chiu, Pi-Hung Tung, Chi-Hsien Huang, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Chin-Chou Wang, Ho-Wen Ko, Ping-Chih Hsu, Yueh-Fu Fang,[...]. Cancers (Basel) 2022
2

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.
A Passaro, N Leighl, F Blackhall, S Popat, K Kerr, M J Ahn, M E Arcila, O Arrieta, D Planchard, F de Marinis,[...]. Ann Oncol 2022
16

Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis.
Katrin Haeussler, Xuan Wang, Katherine B Winfree, Yulia D'yachkova, Sory Traore, Tarun Puri, Howard Thom, Christos Papagiannopoulos, Maria Nassim, Kaisa Taipale. Future Oncol 2022
0

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy.
Matteo Canale, Kalliopi Andrikou, Ilaria Priano, Paola Cravero, Luigi Pasini, Milena Urbini, Angelo Delmonte, Lucio Crinò, Giuseppe Bronte, Paola Ulivi. Cancers (Basel) 2022
2




Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2022
65

Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review.
Francesco Passiglia, Paolo Bironzo, Valentina Bertaglia, Angela Listì, Edoardo Garbo, Giorgio Vittorio Scagliotti. Transl Lung Cancer Res 2022
1


An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer.
Yuexiao Qi, Xiaojun Xia, Lihua Shao, Liyun Guo, Yumei Dong, Jinhui Tian, Lijun Xu, Ruijun Niu, Shihong Wei. Front Oncol 2022
0

First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis.
Chongxiang Chen, Chunning Zhang, Huaming Lin, Qianyin Liu, Limian Wu, Chengzhi Zhou, Jiexia Zhang. Ther Adv Chronic Dis 2022
0

Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC.
Julia Roeper, Sylke Kurz, Christian Grohé, Frank Griesinger. Future Oncol 2021
8

Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.
Tohru Ohmori, Toshimitsu Yamaoka, Koichi Ando, Sojiro Kusumoto, Yasunari Kishino, Ryou Manabe, Hironori Sagara. Int J Mol Sci 2021
14


Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis.
Yi Zhao, Bo Cheng, Zisheng Chen, Jianfu Li, Hengrui Liang, Ying Chen, Feng Zhu, Caichen Li, Ke Xu, Shan Xiong,[...]. Crit Rev Oncol Hematol 2021
9


Hype or hope - Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
Filippo Papini, Janani Sundaresan, Alessandro Leonetti, Marcello Tiseo, Christian Rolfo, Godefridus J Peters, Elisa Giovannetti. Crit Rev Oncol Hematol 2021
5